Records containing: Loss of Chromosome 17p

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2025-03-26
Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma
CLINICAL_TRIALS study record update · 2024-03-20
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
CLINICAL_TRIALS study record update · 2023-06-26
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
CLINICAL_TRIALS study record update · 2022-12-02
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
CLINICAL_TRIALS study record update · 2021-11-05
A Multicenter Study of Ibrutinib Resistance Development and Intervention With Venetoclax (Phase II)
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2019-11-22
Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation
CLINICAL_TRIALS study record update · 2019-07-05
Phase II Open Lable Clinical Study Efficacy and Safety of the Holistic Treatment for Young Patients With High-Risk Multiple Myeloma
CLINICAL_TRIALS study record update · 2019-05-29
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia